Education
About Us
Working with TipRanks
Follow Us
PhoenixBio Co., Ltd. (JP:6190)
:6190
6190 Stock Chart & Stats
¥484.00
¥9.00(2.79%)
At close: 4:00 PM EST
¥484.00
¥9.00(2.79%)
Day’s Range― - ―
52-Week Range¥252.00 - ¥724.00
Previous CloseN/A
Volume3.50K
Average Volume (3M)360.67K
Market Cap
¥1.82B
Enterprise Value¥1.37B
Total Cash (Recent Filing)¥1.04B
Total Debt (Recent Filing)¥503.59M
Price to Earnings (P/E)6.1
Beta0.55
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)19.91
Shares Outstanding4,076,933
10 Day Avg. Volume91,460
30 Day Avg. Volume360,670
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.97
P/FCF Ratio-15.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Humanized PXB-mouse PlatformPhoenixBio's proprietary PXB-mice platform is a durable, high‑barrier asset that supports specialized preclinical ADME/toxicity work. This platform drives recurring demand from pharma for studies and materials, creating long‑term fee-for-service and licensing revenue potential.
Modest Positive Revenue Trend And Recurring Revenue MixReported revenue growth of roughly 4.5% reflects continued market traction in a niche research services market. When combined with fee-for-service and licensing revenue streams, this trend supports repeated engagements and revenue visibility if the company retains repeat pharma customers.
Relatively Stable Equity Base And Moderate LeverageA healthy equity ratio and moderate debt levels give PhoenixBio financial flexibility to operate through cyclical variations and pursue targeted investments. Lower reliance on debt reduces insolvency risk and supports continuity of capital‑intensive research services over time.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows impede PhoenixBio's ability to self‑fund R&D, lab upkeep and capacity expansion. Over several months this raises reliance on external financing or equity, which can dilute stakeholders or constrain strategic investments in the platform.
Negative Operating Margins And ProfitabilityNegative EBIT/EBITDA and net margins indicate operational losses that threaten long‑term sustainability. Without structural margin improvements, PhoenixBio may need to cut costs or reduce investment in services and platform enhancements, limiting competitive positioning.
Declining Asset Base And Revenue VolatilityA declining total asset base coupled with reported revenue fluctuations reduces the firm's balance sheet cushion and operational resilience. Shrinking assets can limit capacity to support larger or simultaneous studies and weaken the company’s ability to scale with big pharma partners.
6190 FAQ
What was PhoenixBio Co., Ltd.’s price range in the past 12 months?
PhoenixBio Co., Ltd. lowest stock price was ¥252.00 and its highest was ¥724.00 in the past 12 months.
What is PhoenixBio Co., Ltd.’s market cap?
PhoenixBio Co., Ltd.’s market cap is ¥1.82B.
When is PhoenixBio Co., Ltd.’s upcoming earnings report date?
PhoenixBio Co., Ltd.’s upcoming earnings report date is May 20, 2026 which is in 65 days.
How were PhoenixBio Co., Ltd.’s earnings last quarter?
PhoenixBio Co., Ltd. released its earnings results on Feb 13, 2026. The company reported ¥19.91 earnings per share for the quarter, beating the consensus estimate of N/A by ¥19.91.
Is PhoenixBio Co., Ltd. overvalued?
According to Wall Street analysts PhoenixBio Co., Ltd.’s price is currently Overvalued.
Does PhoenixBio Co., Ltd. pay dividends?
PhoenixBio Co., Ltd. does not currently pay dividends.
What is PhoenixBio Co., Ltd.’s EPS estimate?
PhoenixBio Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PhoenixBio Co., Ltd. have?
PhoenixBio Co., Ltd. has 4,076,933 shares outstanding.
What happened to PhoenixBio Co., Ltd.’s price movement after its last earnings report?
PhoenixBio Co., Ltd. reported an EPS of ¥19.91 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.112%.
Which hedge fund is a major shareholder of PhoenixBio Co., Ltd.?
Currently, no hedge funds are holding shares in JP:6190
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Technical Analysis
Trans Genic Inc.
―
Takara Bio Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―